Titan: A Compelling Investment Trading Below Fair Value And A Potential Buyout By Its Partner
Partnership agreement with Braeburn Pharmaceuticals has the potential to be very lucrative for Titan.
With Braeburn already owning 11% of Titan's stock, it is possible that Braeburn will take another step and buy out Titan.
Partnership agreements outside of the US have the potential to be unexpected upside for Titan shareholders.
Titan is trading well below the fair value estimate for the company.
Conservatively, Titan should be able to get Probuphine on the market by the end of 2016 providing substantial revenues for the company and its shareholders.
Titan Pharmaceuticals (OTCQB:TTNP) is a very interesting investment opportunity. Coming off of the bad news of an FDA Complete Response Letter regarding its lead drug compound Probuphine, the company once again looks like a rather attractive buy opportunity. It is in the beginning of conducting a clinical trial that should set the stage for FDA approval, and could be a possible takeover target should the company successfully obtain FDA approval. These events should be very lucrative for Titan shareholders and makes it appear as though Titan is largely undervalued given its long term growth potential. The purpose of this article is to discuss the current developments and potential for Titan's pipeline, and then to develop a fair value estimate regarding Titan's stock. Finally, this article will use the filings of Titan to help show why there is a possibility that Titan will be acquired by its partner, and why this would be good for Titan shareholders.